Ozkul, O. Et Al. 2024. The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer. Eurasian Journal of Medical Investigation , vol.8, no.1 , 58-66.

Ozkul, O., ŞAHİN, E., Cabuk, D., SEVER, N., majıdova, n., bayoglu, i. v., ... culha, y.(2024). The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer. Eurasian Journal of Medical Investigation , vol.8, no.1, 58-66.

Ozkul, Ozlem Et Al. "The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer," Eurasian Journal of Medical Investigation , vol.8, no.1, 58-66, 2024

Ozkul, Ozlem Et Al. "The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer." Eurasian Journal of Medical Investigation , vol.8, no.1, pp.58-66, 2024

Ozkul, O. Et Al. (2024) . "The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer." Eurasian Journal of Medical Investigation , vol.8, no.1, pp.58-66.

@article{article, author={Ozlem Ozkul Et Al. }, title={The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer}, journal={Eurasian Journal of Medical Investigation}, year=2024, pages={58-66} }